Oral medication for diabetic macular edema
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests an oral medication that may reduce swelling in the retina caused by diabetes. If you have diabetic macular edema affecting your central vision, this trial could help you preserve or improve your sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Type 1 or Type 2 diabetes.
- You have diabetic macular edema (DME) that affects the center of your vision.
- Your eye may have never been treated, or if treated before, enough time has passed since the last treatment.
- Your vision and eye scan results must meet the study's requirements.
- If you can become pregnant, you must agree to use birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This study tests whether a steroid medication can help reduce swelling in the back of the eye caused by diabetic macular edema, a complication of type 2 diabetes. If you qualify, you may receive this treatment to potentially improve your vision.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.